WALTHAM, Mass., Oct. 19, 2021 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO) ("Thermo
Fisher") announced today that it has priced an offering of
$5.85 billion aggregate principal
amount (the "Offering") of the following notes, each issued at
par:
- $1,000,000,000 aggregate
principal amount of its 18-month floating rate senior notes due
2023 (the "18-Month Floating Rate Notes"),
- $500,000,000 aggregate principal
amount of its floating rate senior notes due 2023 (the "2023
Floating Rate Notes"),
- $500,000,000 aggregate principal
amount of its floating rate senior notes due 2024 (collectively
with the 18-Month Floating Rate Notes and the 2023 Floating Rate
Notes, the "Floating Rate Notes"),
- $1,350,000,000 aggregate
principal amount of its 0.797% senior notes due 2023 (the "2023
Notes"), and
- $2,500,000,000 aggregate
principal amount of its 1.215% senior notes due 2024 (together with
the 2023 Notes, the "Fixed Rate Notes" and, collectively with the
Floating Rate Notes, the "Notes").
The Offering is expected to close on or about October 22, 2021, subject to customary closing
conditions. The Floating Rate Notes will pay interest quarterly.
The Fixed Rate Notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use the
net proceeds of the Offering to pay a portion of the cash
consideration payable for the proposed acquisition of PPD, Inc., a
Delaware corporation. Thermo Fisher may also determine to use a
portion of the net proceeds of the Offering for general corporate
purposes, which may include the acquisition of companies or
businesses, repayment and refinancing of debt, working capital and
capital expenditures or the repurchase of its outstanding equity
securities or it may temporarily invest the net proceeds in
short-term, liquid investments until they are used for their
ultimate purpose.
The joint book-running managers for the Offering are Barclays
Capital Inc., Morgan Stanley & Co. LLC, BofA Securities, Inc.,
Citigroup Global Markets Inc. and Mizuho Securities USA LLC.
The Offering is being made pursuant to an effective registration
statement on Form S-3 filed with the U.S. Securities and Exchange
Commission (the "SEC"). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the Offering and the other
documents that Thermo Fisher has
filed with the SEC for more complete information about Thermo Fisher and this Offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, Thermo
Fisher, the underwriters or any dealer participating in the
Offering will arrange to send you the prospectus if you request it
by calling Barclays Capital Inc. toll-free at 1-888-603-5847;
Morgan Stanley & Co. LLC toll-free at 1-866-718-1649; BofA
Securities, Inc. toll-free at 1-800-294-1322; Citigroup Global
Markets Inc. toll-free at 1-800-831-9146; or Mizuho Securities
USA LLC toll-free at
1-866-271-7403.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes, nor shall there be any
offer, solicitation or sale of the Notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about Thermo Fisher's intended use of
proceeds. These statements involve a number of risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including risks and
uncertainties relating to capital markets conditions, the pending
acquisition of PPD, and completion of the Offering. Additional
important factors and information regarding Thermo Fisher's business that could cause actual
results to differ materially from those indicated by such
forward-looking statements are set forth in the prospectus and
prospectus supplement dated October 19,
2021 related to the Offering, which is on file with the SEC
and available in the "Investors" section of our website under the
heading "SEC Filings," and the documents incorporated by reference
into the prospectus and prospectus supplement. While we may elect
to update forward-looking statements at some point in the future,
we specifically disclaim any obligation to do so, even if
circumstances change and, therefore, you should not rely on these
forward-looking statements as representing our views as of any date
subsequent to today.
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-prices-offering-of-usd-denominated-senior-notes-301404100.html
SOURCE Thermo Fisher Scientific